secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001232524-22-000045
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Pharma Q3 revenue $940.7M (+12% YoY); raises FY guidance mid-point to $3.65B
--------------------------------------------------------------------------------

- Q3 total revenue $940.7M, up 12% YoY; driven by Xywav, Epidiolex, and Rylaze demand.
- Raises 2022 total revenue guidance mid-point to $3.65B, up from prior range.
- Operating cash flow YTD $930M; cash $899.4M; net leverage ratio 2.9x.
- More narcolepsy patients now on Xywav than Xyrem as of October 2022 milestone.
- Pipeline progress: first patients enrolled in Phase 1 JZP815 and Phase 3 Epidyolex in Japan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252422000045/0001232524-22-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252422000045/jazz-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001232524-22-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer